Back to Authors

Cash, David M.

https://orcid.org/0000-0001-7833-616X

A5042212695 | I4405260083

Mayo Clinic

UCL Queen Square Institute of Neurology

Citations 57

P1‐025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI)

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2016.06.772

IC‐P‐142: A Longitudinal Morphometric Study of Familial Alzheimer’s Disease: Results from Dian

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2016.06.172

O1‐07‐01: A Longitudinal Morphometric Study of Familial Alzheimer’s Disease: Results From DIAN

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.329

IC‐P‐106: LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2014.05.112

Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

Proceedings of the National Academy of Sciences | November 5, 2013 | Volume: 110 | Issue: 47 | Pages: No page available

10.1073/pnas.1317918110 | PMID 24194552

Significance Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.
IC‐P‐150: Comparison of accelerated and nonaccelerated MRI in ADNI: Effects on measures of brain and ventricular volumes and rates of atrophy

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2013.05.147

P3–134: Dissociating volume and intensity differences in familial Alzheimer's disease

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1205

P3–095: Comparison of accelerated and nonaccelerated MRI in ADNI: Effects on measures of brain and ventricular volumes and rates of atrophy

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2013.05.1165

P1–269: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene‐dependent?

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2013.05.494

IC‐P‐078: Dissociating volume and intensity differences in familial Alzheimer's disease

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2013.05.075